Pharmaceutical News RSS Feed - Pharmaceutical News

JAT accepts five scientific articles co-authored by UCSD doctoral pharmacy students

JAT accepts five scientific articles co-authored by UCSD doctoral pharmacy students

The Millennium Research Institute (MRI), a nonprofit national research center formed in 2010, and the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego (UCSD) announced today five scientific articles co-authored by UCSD doctoral pharmacy students have been accepted by the Journal of Analytical Toxicology. [More]

Actavis receives FDA approval for Ropinirole ER Tablets

Actavis Group, an international generic pharmaceuticals company, today announced that it received US FDA approval of Ropinirole Extended-Release Tablets, 2mg, 4mg, 6mg, 8mg and 12mg, a generic equivalent to GlaxoSmithKline's Requip XL. [More]

Ocera’s Zysa receives CE Mark to treat IBS-d

Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a condition affecting 10-15% of the Western world. [More]

PharMEDium to present enhanced labeling for ICU services at NTI and Critical Care Expo

Amy Langan, Vice President of Marketing and Business Development, announced that PharMEDium will highlight its enhanced labeling for sterile intravenous compounded ICU Services at the National Teaching Institute (NTI) and Critical Care Exposition, May 19-24, 2012 in Orlando, Florida. [More]

DCI receives FDA approval for PERTZYE NDA to treat EPI

Digestive Care, Inc. (DCI), announced that the company has received U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for PERTZYE, indicated for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis (CF) or other conditions. [More]

Two major reasons to monitor medication use in older patients with chronic pain

Ameritox, the nation's leader in pain medication monitoring, announced today the presentation of a peer-reviewed scientific poster titled "Patterns of Drug Use in the Older Chronic Pain Population" at the American Pain Society Annual Meeting. [More]
Health Canada approves Osiris’ Prochymal to treat acute GvHD in children

Health Canada approves Osiris’ Prochymal to treat acute GvHD in children

Osiris Therapeutics Inc. announced today it has received market authorization from Health Canada to market its stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children. [More]

A decision in N.Y. case on access to abortion pills could impact presidential politics

Politico looks at how a court decision to open Plan B prescriptions to women under the age of 17 could put both President Barack Obama and GOP candidate Mitt Romney on the spot. [More]

Dr. Reddy's launches generic version of PLAVIX

Dr. Reddy's Laboratories announced today that it has launched CLOPIDOGREL TABLETS, USP 75 mg & 300 mg, a bioequivalent generic version of PLAVIX, in the U.S. market on May 18, 2012. [More]

UHN chooses Lexicomp as drug information resource for four hospitals

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Lexicomp has been selected by the University Health Network (UHN) as the drug information resource for its four hospitals located in Toronto, Canada. [More]